{"id":82544,"date":"2025-05-07T18:42:11","date_gmt":"2025-05-07T18:42:11","guid":{"rendered":"https:\/\/www.europesays.com\/fr\/82544\/"},"modified":"2025-05-07T18:42:11","modified_gmt":"2025-05-07T18:42:11","slug":"valneva-lema-sur-penche-sur-ixchiq-apres-des-cas-graves-07-05-2025-a-1813","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/fr\/82544\/","title":{"rendered":"Valneva: l’EMA sur penche sur Ixchiq apr\u00e8s des cas graves – 07\/05\/2025 \u00e0 18:13"},"content":{"rendered":"

(CercleFinance.com) –
\n
\n Valneva
\n<\/a>
\nfait savoir que l’Agence europ\u00e9enne des m\u00e9dicaments (EMA) a lanc\u00e9 une revue de son vaccin Ixchiq contre le chikungunya, sur la base de rapports d’effets ind\u00e9sirables graves chez des personnes \u00e2g\u00e9es.<\/p>\n

Concr\u00e8tement, \u00e0 ce jour, plus de 40,000 doses du vaccin Ixchi\u00ae ont \u00e9t\u00e9 utilis\u00e9es dans le monde mais 17 cas d’effets ind\u00e9sirables graves, dont deux d\u00e9c\u00e8s, ont \u00e9t\u00e9 signal\u00e9s chez des personnes \u00e2g\u00e9es.\n<\/p>\n

\u00c0 titre provisoire, l’utilisation du vaccin est donc suspendue chez les plus de 65 ans, mais maintenue pour les 12 \u00e0 64 ans.\n<\/p>\n

L’EMA souligne toutefois que le lien entre les signalements et la vaccination reste ‘incertain’ et rappelle les contre-indications pour Ixchi en cas d’immunod\u00e9pression.\n<\/p>\n

Si des ajustements ont d\u00e9j\u00e0 \u00e9t\u00e9 faits aux \u00c9tats-Unis et en France, la laboratoire r\u00e9affirme son engagement en mati\u00e8re de s\u00e9curit\u00e9 et juge que le rapport b\u00e9n\u00e9fice\/risque du vaccin demeure favorable.<\/p>\n","protected":false},"excerpt":{"rendered":"(CercleFinance.com) – Valneva fait savoir que l’Agence europ\u00e9enne des m\u00e9dicaments (EMA) a lanc\u00e9 une revue de son vaccin…\n","protected":false},"author":2,"featured_media":82545,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[400,398,408,405,1011,27,72,403,402,399,404,71,401,406,407],"class_list":{"0":"post-82544","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-sante","8":"tag-action-cac-40","9":"tag-bourse-de-paris","10":"tag-boursorama","11":"tag-cotations","12":"tag-fr","13":"tag-france","14":"tag-health","15":"tag-indices-devises","16":"tag-investir","17":"tag-investissement","18":"tag-marche-boursier","19":"tag-sante","20":"tag-sicav","21":"tag-trackers","22":"tag-warrants"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@fr\/114468024824393745","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts\/82544","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/comments?post=82544"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts\/82544\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/media\/82545"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/media?parent=82544"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/categories?post=82544"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/tags?post=82544"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}